WO1996037605A3 - OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE - Google Patents
OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE Download PDFInfo
- Publication number
- WO1996037605A3 WO1996037605A3 PCT/FR1996/000785 FR9600785W WO9637605A3 WO 1996037605 A3 WO1996037605 A3 WO 1996037605A3 FR 9600785 W FR9600785 W FR 9600785W WO 9637605 A3 WO9637605 A3 WO 9637605A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sense oligonucleotides
- ige receptor
- anti sense
- receptor synthesis
- blocking ige
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/337—Chemical structure of the base in alpha-anomeric form
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/952,597 US5892023A (en) | 1995-05-26 | 1996-05-24 | Anti sense oligonucleotides for blocking IgE receptor synthesis |
EP96917549A EP0828827A2 (fr) | 1995-05-26 | 1996-05-24 | OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE |
AU60082/96A AU6008296A (en) | 1995-05-26 | 1996-05-24 | Anti sense oligonucleotides for blocking ige receptor synthe sis |
NO975423A NO975423L (no) | 1995-05-26 | 1997-11-25 | Anti-sense oligonukleotider for blokkering av IgE-reseptorsyntese |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9510718.1A GB9510718D0 (en) | 1995-05-26 | 1995-05-26 | Antisense oligonucleotides |
GB9510718.1 | 1995-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996037605A2 WO1996037605A2 (fr) | 1996-11-28 |
WO1996037605A3 true WO1996037605A3 (fr) | 1996-12-27 |
Family
ID=10775100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1996/000785 WO1996037605A2 (fr) | 1995-05-26 | 1996-05-24 | OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE |
Country Status (7)
Country | Link |
---|---|
US (1) | US5892023A (fr) |
EP (1) | EP0828827A2 (fr) |
AU (1) | AU6008296A (fr) |
CA (1) | CA2222197A1 (fr) |
GB (1) | GB9510718D0 (fr) |
NO (1) | NO975423L (fr) |
WO (1) | WO1996037605A2 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1282699B1 (fr) | 2000-05-04 | 2012-11-21 | Sarepta Therapeutics, Inc. | Composition anti-sens a region d'epissage et methode associee |
WO2004025483A1 (fr) * | 2002-09-16 | 2004-03-25 | Commvault Systems, Inc. | Systeme et procede permettant d'optimiser des operations de stockage |
CA2532795A1 (fr) * | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | Compose antiviral sens et methode permettant de traiter une infection virale induite par un arnss |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20050171044A1 (en) * | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
US20050234002A1 (en) * | 2004-01-23 | 2005-10-20 | Mourich Dan V | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
CA2558262A1 (fr) * | 2004-03-01 | 2005-09-15 | Massachusetts Institute Of Technology | Agents therapeutiques a base d'arni pour le traitement de la rhinite allergique et de l'asthme |
EP4047096A1 (fr) | 2004-06-28 | 2022-08-24 | The University Of Western Australia | Oligonucléotides antisens pour induire l'omission de l'exon et leurs procédés d'utilisation |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
ATE510914T1 (de) * | 2004-07-02 | 2011-06-15 | Avi Biopharma Inc | Antisinn antibakterielle verfahren und verbindungen |
US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US8329668B2 (en) * | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8524676B2 (en) * | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
LT2024499T (lt) | 2006-05-10 | 2018-02-26 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
WO2009086469A2 (fr) * | 2007-12-28 | 2009-07-09 | Avi Biopharma, Inc. | Agents immunomodulatoires et procédés d'utilisation |
EP3428278A1 (fr) * | 2008-10-24 | 2019-01-16 | Sarepta Therapeutics, Inc. | Compositions de saut d'exon multiples pour dmd |
EP2376633A1 (fr) * | 2008-12-17 | 2011-10-19 | AVI BioPharma, Inc. | Compositions antisens et méthodes de modulation de l'hypersensibilité de contact ou de la dermatite de contact |
CN103003430A (zh) | 2009-11-12 | 2013-03-27 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
CA2779830C (fr) | 2009-11-13 | 2020-07-21 | Avi Biopharma, Inc. | Compose antiviral antisens et methode de traitement d'une infection par le virus grippal |
KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
WO2012031243A2 (fr) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | Molécules d'arnds comportant des analogues oligonucléotidiques ayant des liaisons entre sous-unités et/ou des groupes terminaux modifiés |
EA202090338A1 (ru) | 2011-11-18 | 2021-04-30 | Сарепта Терапьютикс, Инк. | Функционально-модифицированные олигонуклеотиды и их субъединицы |
EA202090946A3 (ru) | 2013-03-14 | 2021-07-30 | Сарепта Терапьютикс, Инк. | Композиции, обеспечивающие пропускание экзонов, для лечения мышечной дистрофии |
NZ631289A (en) | 2013-03-15 | 2017-08-25 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
EP3302489A4 (fr) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | Procédés et composés pour le traitement de maladies et d'états pathologiques associés aux lymphocytes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021317A1 (fr) * | 1992-04-16 | 1993-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ISOLATION, CARACTERISATION ET UTILISATION DE LA SOUS-UNITE HUMAINE β DU RECEPTEUR DE HAUTE AFFINITE POUR L'IMMUNOGLOBULINE E |
WO1995009002A1 (fr) * | 1993-09-30 | 1995-04-06 | University Of Pennsylvania | Methode d'inhibition de la phagocytose |
-
1995
- 1995-05-26 GB GBGB9510718.1A patent/GB9510718D0/en active Pending
-
1996
- 1996-05-24 US US08/952,597 patent/US5892023A/en not_active Expired - Fee Related
- 1996-05-24 WO PCT/FR1996/000785 patent/WO1996037605A2/fr not_active Application Discontinuation
- 1996-05-24 AU AU60082/96A patent/AU6008296A/en not_active Abandoned
- 1996-05-24 EP EP96917549A patent/EP0828827A2/fr not_active Withdrawn
- 1996-05-24 CA CA002222197A patent/CA2222197A1/fr not_active Abandoned
-
1997
- 1997-11-25 NO NO975423A patent/NO975423L/no not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993021317A1 (fr) * | 1992-04-16 | 1993-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | ISOLATION, CARACTERISATION ET UTILISATION DE LA SOUS-UNITE HUMAINE β DU RECEPTEUR DE HAUTE AFFINITE POUR L'IMMUNOGLOBULINE E |
WO1995009002A1 (fr) * | 1993-09-30 | 1995-04-06 | University Of Pennsylvania | Methode d'inhibition de la phagocytose |
Non-Patent Citations (4)
Title |
---|
BHATTI, L. ET AL.: "Inhibition of B cell proliferation by antisense DNA to both alpha and beta forms of Fc epsilon R II.", CELL IMMUNOL, (1992 OCT 1) 144 (1) 117-30, XP000561855 * |
FOURNIER, S. ET AL.: "Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation.", BLOOD, (1994 SEP 15) 84 (6) 1881-6., XP000609085 * |
FU-TONG, LIU ET AL.: "CDNA HETEROGENEITY SUGGESTS STRUCTURAL VARIANTS RELATED TO THE HIGH-AFFINITY IGE RECEPTOR", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 85, no. 15, pages 5639 - 5643, XP000005253 * |
ZON, G.: "Oligonucleotide analogues as potential chemotherapeutic agents", PHARMACEUTICAL RESEARCH, VOL. 5 (1988); 539 - 549, XP002008915 * |
Also Published As
Publication number | Publication date |
---|---|
AU6008296A (en) | 1996-12-11 |
US5892023A (en) | 1999-04-06 |
NO975423D0 (no) | 1997-11-25 |
CA2222197A1 (fr) | 1996-11-28 |
NO975423L (no) | 1997-11-25 |
GB9510718D0 (en) | 1995-07-19 |
EP0828827A2 (fr) | 1998-03-18 |
WO1996037605A2 (fr) | 1996-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996037605A3 (fr) | OLIGONUCLEOTIDES ANTISENS POUR BLOQUER LA SYNTHESE DU RECEPTEUR DE L'IgE | |
ZA964738B (en) | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures | |
IL122484A0 (en) | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures | |
NO20063000L (no) | Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav. | |
NO973922L (no) | Nye taxoider, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene | |
IL161829A (en) | 1,2,4 - thiadiazole derivatives, some of which are novel and pharmaceutical compositions comprising the same for treating disorders mediated by melanocortin receptor modulators | |
ZA964873B (en) | Tricot-like pouch for the delivery of topical drugs and cosmetics. | |
CA2190588A1 (fr) | Analogues de nucleotides de pteridine sous forme d'echantillons d'adn fluorescents | |
WO2002099051A3 (fr) | Nit utilises comme modificateurs de la voie p53 et procedes d'utilisation | |
ZA979550B (en) | Method for the preparation of methylidene malonate nanoparticles, nanoparticles which optionally contain one or more biologically active molecules, and pharmaceutical compositions containing them. | |
EP0871496A4 (fr) | ||
WO2001047944A3 (fr) | Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants | |
WO2001087227A3 (fr) | Methodes et compositions a base de micelles polymeres sensibles au ph, permettant d'augmenter la puissance d'agents therapeutiques | |
AU1062997A (en) | Novel polymer supports for nucleic acid synthesis | |
NO305903B1 (no) | Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater | |
WO1997004788A3 (fr) | Utilisation de glycosides de calendula dans le traitement du psoriasis | |
HK1015789A1 (en) | Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use. | |
AU2001251613A1 (en) | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers | |
DE69600601D1 (de) | Heterocyclische, aromatische Verbindungen, pharmazeutische und kosmetische Zusammensetzungen,die sie enthalten, und Verwendungen. | |
WO2000029623A3 (fr) | Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques | |
EP0775745A3 (fr) | Aptamères capables d'inhiber la cathépsine G | |
HUP9900317A2 (hu) | Nukleinsavval való transzfektálásra használható gyógyszerkészítmények és felhasználásuk | |
NO305948B1 (no) | Basisk substituerte benzolguanidiner, deres anvendelse til fremstilling av medikament eller diagnostikum samt medikament inneholdende forbindelsen | |
DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
WO2001040521A3 (fr) | Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08952597 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2222197 Country of ref document: CA Ref country code: CA Ref document number: 2222197 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996917549 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996917549 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996917549 Country of ref document: EP |